Msln (Mesothelin), Antxr1 (Tem8), and Muc3a Are the Potent Antigenic Targets for Car T Cell Therapy of Gastric Adenocarcinoma Publisher Pubmed



Sotoudeh M^{1, 2} ; Shirvani SI³ ; Merat S^{1, 4} ; Ahmadbeigi N³ ; Naderi M³
Source: Journal of Cellular Biochemistry Published:2019

Abstract

Gastric adenocarcinoma is usually diagnosed in late stages, necessitating the use of different therapeutic modalities. Currently, antibody-based therapies have also been approved through with limited clinical efficacy. Reinforcing antibody-based immunotherapy by using chimeric antigen receptor (CAR) T cells may enhance the approach. However, the cells can cause severe on-target and off-tumor toxicities owing to their higher sensitivity to low-level antigen expressions. To address the need for safe and reliable targets, we made a bioinformatics pipeline by which we screened overexpressed genes in the disease for off-tumor sites in many normal tissues. Our inspection showed that MSLN (Mesothelin), ANTXR1 (TEM8), and MUC3A are the probable targets of CAR T cell therapy in gastric adenocarcinoma. The proposed antigenic targets might respond to the need to simultaneously target multiple antigens in a tumor matrix to prevent resistance. © 2018 Wiley Periodicals, Inc.